Compass Therapeutics gets Nasdaq notice over $1 bid rule
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Compass Therapeutics, Inc. received a Nasdaq deficiency notice after its closing bid price fell below the $1.00-per-share minimum for 30 consecutive business days. The notice has no immediate effect, and CMPX common stock continues to trade on The Nasdaq Capital Market. The company has 180 calendar days, through May 18, 2027, to regain compliance. A closing bid of at least $1.00 per share for 10 consecutive business days before then would meet the stated cure test. If CMPX does not meet the deadline, it may qualify for a second 180-day period if it satisfies other listing standards and notifies Nasdaq of its intent to cure by effecting a reverse stock split, if necessary. Otherwise, the stock may become subject to delisting.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Major pointBid price stayed below $1.00 for 30 consecutive business days, triggering a Nasdaq deficiency notice.
Filing Explained
If Compass Therapeutics qualifies for a second compliance period, a reverse split is a possible cure; it would reduce the share count and proportionally raise the per-share price, without changing company value by the split itself.
8-K Event Classification
Key Figures
Key Terms
Minimum Bid Price Requirement regulatory
Nasdaq Listing Rule 5810(c)(3)(A) regulatory
Nasdaq Hearings Panel regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Nasdaq send CMPX a deficiency notice?
How can CMPX regain Nasdaq minimum bid-price compliance?
Can CMPX get more time if it misses the May 18, 2027 deadline?
AI-generated analysis. How Rhea-AI works. Not financial advice.